In short
Clinical trials are investigating Sqy51 in children and adults with genetically confirmed Duchenne muscular dystrophy. The studies aim to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, which means how the body handles the treatment and what effects it has in the body.
Key points
- Sqy51 is being studied in an early Phase 1/2 trial for people with Duchenne muscular dystrophy. The trial includes both paediatric and adult patients with a genetically confirmed diagnosis. Researchers are mainly looking at safety, tolerability, pharmacokinetics, and pharmacodynamics. The main endpoints include adverse events, serious adverse events, and treatment stops because of side effects. The study is authorised and plans to enroll 12 participants.
Trial overview
The available study is a Phase 1/2 interventional trial of Sqy51 in people with Duchenne muscular dystrophy. It is authorised and planned for 12 participants. The intervention listed is SQY51 given by intravenous use.
Who can participate
The trial includes paediatric and adult patients with a genetically confirmed diagnosis of Duchenne muscular dystrophy. This means the diagnosis must be proven by genetic testing, not only by symptoms or a clinical exam.
What is being measured
The main safety measures are the type, frequency, severity, timing, and relationship to Sqy51 of adverse events, discontinuations due to adverse events, and serious adverse events. In simple terms, researchers want to know what medical problems happen, how often they happen, how serious they are, when they happen, and whether they may be linked to the study treatment.
The brief summary also says that Phase 1 focuses on safety and tolerability, while Phase 2a looks at safety and tolerance after 49 weeks of multiple dosing. These are early research goals that help show whether the study treatment can be given and followed over time.
Study phase and design
This study is described as a Phase 1/2 trial, which means it combines early safety testing with an early look at how the treatment behaves in the body and what effects it may have. The study is interventional, so participants receive the study treatment as part of the research plan.
The summary also mentions a Phase 2a part and an extension phase. The extension phase has the same primary and secondary objectives as Phase 2a, except that another muscle biopsy will not be performed.
Endpoints and follow-up
The primary endpoint focuses on adverse events, serious adverse events, and discontinuations due to adverse events. These endpoints are standard ways to measure whether a study treatment appears safe enough to continue testing.
The trial also follows participants through a 49-week multiple dosing period in Phase 2a. The source data do not provide more detail on secondary outcomes beyond the statement that the extension phase keeps the same goals as Phase 2a, except for no additional muscle biopsy.
What this means for patients
For patients and families, this study is an early step in learning whether Sqy51 can be studied safely in Duchenne muscular dystrophy. Because the trial includes both children and adults, it is aimed at a wide age range within this condition. The study is not yet about proving long-term benefit; it is mainly about safety and early research signals.